Dr. Toby J. Briskin

Endocrinology
19999 Rockside Rd, 
Bedford, OH 
19999 Rockside Rd, 
Bedford, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Toby Briskin is an Endocrinologist in Bedford, Ohio. Her top areas of expertise are Type 2 Diabetes (T2D) and Obesity.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

19999 Rockside Rd, Bedford, OH 44146

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally
A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally
Enrollment Status: Terminated
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
Lyme Test Indication Combinations (LyTIC) Study
Lyme Test Indication Combinations (LyTIC) Study
Enrollment Status: Terminated
Publish Date: December 13, 2018
Intervention Type: Diagnostic test
View 10 Less Clinical Trials

2 Total Publications

Correction to: Evaluating the User Performance and Experience with a Re-Engineered 4mm × 32G Pen Needle: A Randomized Trial with Similar Length/Gauge Needles.
Correction to: Evaluating the User Performance and Experience with a Re-Engineered 4mm × 32G Pen Needle: A Randomized Trial with Similar Length/Gauge Needles.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: April 19, 2019
Similar Doctors
Expertise in
42
conditions
Dr. Betul A. Hatipoglu
Endocrinology
Expertise in
42
conditions
Dr. Betul A. Hatipoglu
Endocrinology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (7.7 miles away)
216-844-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Betul Hatipoglu is an Endocrinologist in Cleveland, Ohio. Dr. Hatipoglu is highly rated in 42 conditions, according to our data. Her top areas of expertise are Cushing's syndrome, Cushing's disease, Type 1 Diabetes (T1D), Islet Cell Transplantation, and Pancreatectomy.

Expertise in
14
conditions
Dr. Anca Avram
Endocrinology
Expertise in
14
conditions
Dr. Anca Avram
Endocrinology

The Metrohealth System

2500 Metrohealth Dr, 
Cleveland, OH 
 (9.1 miles away)
216-778-7800
Languages Spoken:
English
See accepted insurances

Anca Avram is an Endocrinologist in Cleveland, Ohio. Dr. Avram is highly rated in 14 conditions, according to our data. Her top areas of expertise are Thyroid Cancer, Osteopenia, Melorheostosis with Osteopoikilosis, Melorheostosis, and Thyroidectomy.

Expertise in
41
conditions
Dr. Divya Yogi
Endocrinology
Expertise in
41
conditions
Dr. Divya Yogi
Endocrinology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (7.8 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Divya Yogi is an Endocrinologist in Cleveland, Ohio. Dr. Yogi is highly rated in 41 conditions, according to our data. Her top areas of expertise are Prolactinoma, Pituitary Tumor, Cushing's disease, and Empty Sella Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Briskin's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile